The Indianapolis-based startup is developing drugs targeting brain and bowel disorders.
West Lafayette-based Bioanalytical Systems’ latest executive departure comes amid recent signs of stability, turnaround and growth for a company that just three years ago was on the verge of sinking.
Eli Lilly and Co.’s breakthroughs during Wood’s 18-year tenure included biosynthetic insulin and the category-smashing antidepressant Prozac.
Eli Lilly and Co.’s treatment Emgality and Teva Pharmaceutical’s drug Ajovy were approved within months of each other in 2018.
For a startup that has raised an eye-popping $71 million in just three years, Outpost Medicine LLC likes to keep a low profile. The young company, which is developing drugs for urinary and gastrointestinal disorders, is headquartered in small, unmarked space at the Parkwood Crossing office complex on East 96th Street. It has issued only a […]
Eli Lilly and Co.’s stock jumped Thursday after midstage research on an experimental diabetes drug showed significant weight loss in patients. The news took a toll on shares of rival Novo Nordisk.
Dr. Dan Skovronsky needs to deliver on the drugmaker’s audacious goal of launching 20 new medicines by 2023.
An independent data-monitoring committee found that the medicine, lanabecestat, was unlikely to meet the goals of the studies, one for early Alzheimer’s and the other for mild dementia related to the disease.
Under the agreement, Lilly will pay Sigilon Therapeutics up to $410 million if the technology hits certain milestones.
The Food and Drug Administration proposal will create new opportunities for drugmakers after repeated failures from companies including Indianapolis-based Eli Lilly and Co.
A slimmed-down Eli Lilly and Co., thousands of employees lighter after its biggest restructuring in nearly a decade, is now looking high and low for deals to bulk up its drug pipeline.
The 5-year-old Carmel biotech has won plenty of attention from Wall Street and has secured more than $100 million through licensing deals and a stock offering to help fund expensive clinical trials.
Pharmaceutical companies have introduced medicines to treat dependence, reverse overdoses and deal with opioid side effects. But few effective and economically viable alternatives to addictive painkillers have emerged from the laboratory.
After struggling for more than 20 years to develop cancer drugs without success, West Lafayette-based Endocyte Inc. is pausing it own R&D efforts to concentrate on a potential blockbuster drug from a German chemical company.
The companies say the drug, now in late-stage clinical trials, could be more effective for pain treatment than opioids—a dangerous category of pain killers that includes hydrocodone, morphine and fentanyl—without the abuse potential of such medications.
The court's unanimous ruling Monday means a loss of billions in sales to makers of original versions of biologic drugs.
News that federal regulators rejected Lilly’s drug for arthritis sent the stock tumbling more than 5 percent Monday, and sent surprised analysts searching for answers.